SPRY — ARS Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $429.61m
- $382.44m
- $84.28m
Brief: Eurneffy Approved In The EU
Brief: ARS Pharma To File Supplemental Application In U.S. For Lower Dose Neffy In Q3
U.S. STOCKS ON THE MOVE-Revance Therapeutics, Insulet, StepStone
ARS Pharma gains as FDA greenlights nasal spray for allergic reactions
US FDA approves first nasal spray for allergic reactions (updated)
U.S. FDA approves first nasal spray for allergic reactions
Brief: FDA Approves First Nasal Spray For Treatment Of Anaphylaxis
ARS Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
ARS Pharmaceuticals Inc expected to post a loss of 12 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Infinera, Landbridge, Tempus AI
U.S. STOCKS ON THE MOVE-ARS Pharma, Digital Realty, Capricor Therapeutics
U.S. STOCKS ON THE MOVE-Protagonist Therapeutics, Infinera, GEO Group
ARS Pharma climbs as EU regulator recommends approval for nasal spray
EU regulator recommends approval for ARS pharma's nasal spray alternative to EpiPen (updated)
EU regulator recommends approval for ARS pharma's nasal spray alternative to EpiPen
ARS Pharmaceuticals Inc expected to post a loss of 13 cents a share - Earnings Preview
Brief: ARS Pharmaceuticals CHMP Opinion On Neffy Marketing Authorization Application Expected In Q2 2024
Brief: ARS Pharmaceuticals Submits Response To FDA Complete Response Letter For neffy (Epinephrine Nasal Spray)
U.S. RESEARCH ROUNDUP-Darden Restaurants, Fedex, Nike